Article
Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
The Prostate - 1 Sept 2015
Liss Michael A, Xu Jianfeng, Chen Haitao, Kader A Karim
Abstract excerpt
BACKGROUND: To investigate the ability of the prostate genetic score (PGS-33), a germ-line biomarker of prostate cancer (PCa) risk, to categorize men participating in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. METHODS: We obtained the genetic data from the Cancer Genetic Markers of Susceptibility (CGEMS), a nested case control study examining germ-line DNA in the screened arm of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
